AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03924505 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dissemination
Description: Our comparison group receives dissemination of best practice recommendations for naloxone implementation.
Study NCT04633603 — intervention group
Intervention type: DEVICE
Intervention: FeverFriend mobile application
Description: Registration, documentation of patients profile, documentation of fever events, following advice regarding the patient and the care-giver, documentation of follow up notifications.
Study NCT02211092 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Description: A 12 week individually tailored home-based physical activity program with goal-setting, a physical activity self-monitoring technique, and weekly telephone calls provided by the intervener for coaching and support.
Study NCT02211092 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Access to usual community resources but no active lifestyle coaching.
Study NCT01399970 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Teleconsultation Arm (MTA)
Description: In addition to a face-to-face visit at baseline, patients will conduct mobile visits at home every two weeks. The general practitioner of choice will perform examinations, such as laboratory or occasionally pregnancy tests every 4 weeks according to the treatment guidelines.
Study NCT01399970 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Outpatient Consultation Arm (OCA)
Description: Patients will receive routine outpatient care at the clinic according to the treatment guidelines, and will be scheduled for outpatient visits every 4 weeks.
Study NCT03807401 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prismatic goggles
Description: Goggles inducing a lateral displacement of the virtual field of ten degrees. Participants will be asked to wear those goggles during adaptation session and to perform pointing movement toward visual target.
Study NCT03807401 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality device
Description: The lateral displacement will be simulated thanks to a virtual reality environment. Participants will wear an Oculus Rift instead of the prismatic goggles and will perform pointing movement as well.
Study NCT03807401 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prismatic goggles
Description: Goggles inducing a lateral displacement of the virtual field of ten degrees. Participants will be asked to wear those goggles during adaptation session and to mentally perform pointing movement toward visual target. There will be no concurrent movement execution.
Study NCT04296851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niclosamide
Description: The subjects will be randomly assigned in a 2:1 ratio to receive niclosamide or identical-appearing placebo tablets orally for 6 months: niclosamide 650mg once a day in arm 1, placebo once a day in arm 2.
Study NCT04296851 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The subjects will be randomly assigned in a 2:1 ratio to receive niclosamide or identical-appearing placebo tablets orally for 6 months: niclosamide 650mg once a day in arm 1, placebo once a day in arm 2.
Study NCT01967095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: Cycle 1, week 1 (D1-D7) will consist of pulse dose erlotinib on D1 \& D2 without daily low dose erlotinib on D3-7. For all subsequent weeks, patients will take high dose erlotinib on D1 \& D2, \& will receive erlotinib 50 mg oral daily x 5 days on days 3-7. On days 1 \& 2, patients will take one of the following doses of erlotinib, depending on the dose cohort they are enrolled in: Dose level 1 600 mg oral daily on D1, D2 Dose level 2 750 mg oral daily on D1, D2 Dose level 3 900 mg oral daily on D1, D2 Dose level 4 1050 mg oral daily on D1, D2. An additional Dose -1 (pulse dose erlotinib on D1, D2 with 25 mg oral daily x 5 days in D3-D7) will be reserved, in the unlikely situation that Dose 1 is proved too toxic. If Dose -1 is tolerated well (600mg oral daily D1, D2 \& 25mg oral daily D3-D7), pulse dose escalation can continue as described above, with erlotinib at the daily low dose of 25 mg oral on D3-D7.
Study NCT04074382 — intervention group
Intervention type: OTHER
Intervention: Online Questionnaires
Description: We will use online questionnaires to complete research into functional outcomes after trauma
Study NCT04074382 — intervention group
Intervention type: OTHER
Intervention: Qualitative Interviews
Description: We will undertake qualitative interviews (remote or face to face) to shed more light on reasons for functional outcomes after trauma
Study NCT04202315 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Utilizing Virtual Reality during external fixator removal in outpatient clinic setting.
Study NCT03453996 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Computerized clinical decision support intervention. This intervention consists of 2 decision support components for CI-AKI prevention:~1. Estimation of safe contrast limit to reduce the relative risk of CI-AKI by 20% (ePRISM Acute Kidney Injury Model with Contrast Sensitivities and Dialysis Risk software from Health Outcomes Sciences)~2. Patient weight and left ventricular end diastolic pressure (LVEDP) based intravenous crystalloid fluid recommendation.
Study NCT03453996 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Usual procedural care provided by cardiologist without introduction of the computerized clinical decision support information.
Study NCT01078298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varenicline
Description: varenicline tablets titrated to 1 mg BID during 1st week and then 1 mg BID for 11 weeks
Study NCT01078298 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablets matched in appearance and dosage to varenicline tablets
Study NCT01611428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipragliflozin
Description: Oral and Intravenous (i.v.)
Study NCT02376296 — intervention group
Intervention type: DRUG
Intervention: docetaxel
Description: 3-weekly docetaxel therapy (starting dose of 75 mg/m2)
Study NCT02376296 — intervention group
Intervention type: OTHER
Intervention: Blood draws
Description: Blood draws for determination of docetaxel plasma levels and exposure (AUC)
Study NCT03318081 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive function rehabilitation and bias modification
Description: cognitive rehabilitation focus on the deficits executive funcitin and elevated cognitive bias
Study NCT00655512 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pimecrolimus 1% cream
Description: twice a day one fingertip at the testareas (forehead and forearm/back of the hand) for 4 weeks
Study NCT00655512 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydrocortisonacetat 1% cream
Description: twice a day one fingertip at the testareas (forehead and forearm/back of the hand) for 4 weeks
Study NCT00655512 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: betamethasonvalerat 0,1% cream
Description: twice a day one fingertip at the testareas (forearm/back of the hand) for 4 weeks
Study NCT00655512 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clobetasol-17-propionat 0,05% cream
Description: twice a day one fingertip at the testareas (forearm/back of the hand) for 4 weeks
Study NCT00655512 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: twice a day one fingertip at the testareas (forehead and forearm/back of the hand) for 4 weeks
Study NCT03218228 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: implants in periodontitis
Description: it targets immediate implant placement in patients suffering from aggressive periodontitis
Study NCT03218228 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: implants in periodontitis
Description: it targets immediate implant placement in patients suffering from aggressive periodontitis
Study NCT00939471 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Relieva™ Balloon Sinuplasty™ System
Description: Balloon dilation will be performed using endoscopic equipment with video documentation capability.
Study NCT02585388 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: Vinorelbine metronomic at 50 mg (1 tablet at 20 mg and 1 tablet at 30mg),per oral, 3 times per week. One dose level reduction is authorized at 30 mg per day.when stopping over 3 consecutive weeks due to toxicity, treatment should be permanently discontinued
Study NCT02585388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Vinorelbine metronomic at 50 mg (1 tablet at 20 mg and 1 tablet at 30mg),per oral, 3 times per week. One dose level reduction is authorized at 30 mg per day.when stopping over 3 consecutive weeks due to toxicity, treatment should be permanently discontinued
Study NCT02585388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Lestrozole at 2,5 mg every day , per oral
Study NCT02585388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Anastrozole at 1 mg every day, per oral
Study NCT04517045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dachengqi decoction
Description: Raw rhubarb 30g, Glauber's salt 30g, Citrus aurantium 20g, Magnolia officinalis 20g. The decoction was decocted uniformly in the decoction room of Xinhua Hospital, Shanghai Jiaotong University School of Medicine, and decocted 200 mL thickly, fed via nasogastric tube/nasal intestine tube and enema, 1 dose/d, and continued treatment until the end of the trial
Study NCT04517045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: probiotic L9
Description: L92 2 tablets/time, tid, oral or nasal feeding
Study NCT04517045 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Conventional treatment
Description: Conventional treatment
Study NCT04517045 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: Conventional treatment
Study NCT01663194 — intervention group
Intervention type: PROCEDURE
Intervention: primary percutaneous coronary intervention, each groups
Description: All primary PCI procedures were performed using the standard femoral approach with a 7-French guiding catheter for each patients. After administration of 5,000 IU of intravenous heparin (70 U/Kg) and a 300 mg loading dose of clopidogrel, direct stenting was performed whenever possible, and in the remaining cases, balloon pre-dilatation was performed. The operator determined the choice of stents (bare metal or drug-eluting stent).
Study NCT02703818 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Senza
Description: Spinal Cord Stimulation
Study NCT01794598 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Receiving educational material of depression care
Description: The educational material provides patients about depression management
Study NCT01794598 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Receiving educational material of depression care
Description: The educational material provides patients about depression management
Study NCT03385369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382
Description: Single dose of MEDI0382
Study NCT03241264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND-L02-s0201
Description: Specified dose on specified day
Study NCT00872014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 386
Description: Two doses of AMG 386 (15 mg/kg) IV QW will be studied
Study NCT00872014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 386
Description: Two doses of AMG 386 (10 mg/kg) IV QW will be studied
Study NCT00872014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib 400 mg PO BID orally twice daily in an every 4 week dosing schedule for 15mg/kg cohort \& 10mg/kg cohort
Study NCT02102464 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LipiFlow treatment
Description: The LipiFlow® Thermal Pulsation System is a prescription device intended for the application of localized heat and pressure therapy in adult patients with chronic cystic conditions of the eyelids, including meibomian gland dysfunction, also known as evaporative dry eye or lipid deficiency dry eye.
Study NCT02404493 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EpiCeram Skin Barrier Emulsion
Description: EpiCeram Skin Barrier Emulsion
Study NCT02404493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% Colloidal Oatmeal Balm
Description: Experimental Product 1% Colloidal Oatmeal Balm
Study NCT03435601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anifrolumab
Description: IV Administration of Anifrolumab 300 mg every 4 weeks from week 0 to week 20 for a total of 6 doses.~At week 24 patients will continue the current study for another 8 weeks to complete a 12-week safety follow-up after the last dose of investigational products (last dose of investigational product will be given at week 20).~The total study duration could be up to approximately 36 weeks (including the screening period).
Study NCT03435601 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo IV administration Q4W, a total of 6 doses At week 24 patients will continue the current study for another 8 weeks to complete a 12-week safety follow-up after the last dose of investigational products (last dose of investigational product will be given at week 20).~The total study duration could be up to approximately 36 weeks (including the screening period).
Study NCT01611818 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Low Intensity Internet-delivered psychotherapy
Description: Patients will be contacted by a researcher trained in psychotherapy. Patients can ask for questions or advice to psychotherapists during the study
Study NCT01611818 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Self-guided Internet delivered psychotherapy
Description: No contact with the therapists over the treatment period will be done.
Study NCT01611818 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Improved treatment as usual
Description: Any kind of treatment administered by the GP to the patient with depression
Study NCT01487304 — intervention group
Intervention type: DRUG
Intervention: Marketed low dose hormone replacement therapy
Description: A low dose of marketed HRT products prescribed at the discretion of the treating physician
Study NCT03463434 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Low Pressure-LAL
Description: Continuous Low Pressure/Low Air Loss Mattress for Pressure injury treatment
Study NCT01175564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Four increasing doses levels of a single dose and two increasing dose levels of 6 days repeated dose of TC-5214 tablet
Study NCT01175564 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet, single dose and 6 days repeated dose
Study NCT03553849 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Very low calorie diet
Description: The VLCD is a prescribed diet with well-balanced macro and micronutrients. It is intended for significant weight loss in a short period of time, is intended only for the extremely obese, and must be completed under the supervision of a trained physician.
Study NCT03385369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose of placebo
Study NCT03385369 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of placebo
Study NCT04621162 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Expectations (initial)
Description: A positive expectation of the effect of motor imagery will be given before beginning the mental practice of imagination. This task will generate hypoalgesia
Study NCT04621162 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Negative Expectations (initial)
Description: A negative expectation of the effect of motor imagery will be given before beginning the mental practice of imagination. This task will not generate hypoalgesia
Study NCT04621162 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Neutral Expectations (initial)
Description: This group will act as a control. No expectations will be given that will influence the participant.
Study NCT04621162 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Expectations (during intervention)
Description: A positive expectation will be given during the performance of the mental practice. This is working very well
Study NCT04621162 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Negative Expectations (during intervention)
Description: A negative expectation will be given during the performance of the mental practice. This is working very bad
Study NCT04621162 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Neutral Expectations (during intervention)
Description: This group will act as a control. No expectations will be given that will influence the participant.
Study NCT02799173 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RANKL/OPG ratio
Study NCT02799173 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bone densitometry
Study NCT02799173 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fan beam CT scan
Study NCT02799173 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Doppler ultrasound
Study NCT03337035 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intranasal oxytocin
Description: 4-24 IU per day, dosage gradually increases
Study NCT03337035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intranasal oxytocin
Description: 4-24 IU per day, dosage gradually increases
Study NCT03337035 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: oral probiotics
Description: 200 million cfu per day
Study NCT03337035 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: oral placebo
Description: 2 pills per day
Study NCT00494221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD2171
Description: oral tablet
Study NCT00494221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)
Description: intravenous infusion
Study NCT00494221 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)
Description: intravenous infusion
Study NCT00494221 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cediranib
Description: oral tablet
Study NCT02563691 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic radiotherapy
Description: Patients will receive ADT for a minimum of 1 year. After this, an intermittent hormone therapy approach will be taken.~The prostate (if not previously treated) will be treated to a dose of 35-40 Gy in 5 fractions. All visible nodal metastases will be treated to a dose of 30-35 Gy in 5 fractions. Non-spine bone metastases will be treated to a dose of 30-40 Gy in 5 fractions. Metastases in the brain, spine, lung, liver, and adrenal will be treated according to established SRT policies at the Sunnybrook Odette Cancer Centre. Comprehensive SRT should be delivered within 3 months of starting ADT.
Study NCT03973255 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: Posturography, Whole body vibration
Study NCT02477449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: istaroxime
Description: 8 subjects in 0.25ug/kg/min group were administrated Istaroxime + 0.9% NS fo12 subjects in 0.5ug/kg/min or 1.0 ug/kg/min group randomly received Istaroxime placebo + 0.9% NS (2 subjects), 0.9% NS alone (2 subjects) and Istaroxime + 0.9% NS (8 subjects).
Study NCT02477449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9% Saline (NS)
Description: infusion for 24 hours
Study NCT04267471 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: Tai Chi is a traditional Chinese mind-body exercise, which combines deep-breath relaxation and gentle movements in sequence with meditation. Each session of Tai Chi will last 60 minutes, including a 10-minute warm-up, a 40-minute Tai Chi practice and a 10-minute cool-down.
Study NCT04267471 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Walking
Description: Each session of walking will last 60 minutes, including a 10-minute warm-up, a 40-minute walking and a 10-minutes cool-down.
Study NCT02036255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taurolidine Urokinase
Study NCT02036255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taurolidine Heparin
Study NCT02036255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taurolidine Heparin
Study NCT03544229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-906 Maleate
Description: TAK-906 maleate capsules.
Study NCT03544229 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-906 maleate placebo-matching capsules.
Study NCT03361098 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10mg
Description: Dapagliflozin 10mg oral tablet once daily
Study NCT03361098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg
Description: Dapagliflozin 10mg oral tablet once daily